Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This educational activity is supported by educational grants from AstraZeneca, Bristol Myers Squibb, and Daiichi Sankyo, Inc.

School of Breast Oncology® Live Video Webcast: Clinical Updates From Chicago

Release Date: September 3, 2020
Expiration Date: September 3, 2021

Activity Overview

This online, on-demand virtual symposium brings together a renowned group of experts in the management of breast oncology, who discuss new treatment options and new indications for approved agents. Over the past few years, several new classes of agents have been added to the treatment armamentarium for breast cancer. Many of these agents require molecular-based selection, highlighting the heterogeneity of breast cancers and the increasing need to personalize treatment strategies based on underlying tumor biology; the use of biomarkers and molecular assays; and careful assessment of the benefit-risk ratio for particular therapies and patient comorbidities. This program is an extension of the annual School of Breast Oncology®, and it provides an additional forum for clinicians to keep pace with rapidly emerging data and advancing treatment paradigms in breast cancer.

This educational activity is an archive of the live virtual symposium held on August 12, 2020.

Acknowledgment of Commercial Support.

This educational activity is supported by educational grants from AstraZeneca, Bristol Myers Squibb, and Daiichi Sankyo, Inc.


Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with breast cancer. Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals involved in the management of breast cancer will also be invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Summarize data sets from recently reported clinical trials investigating novel approaches for the treatment of breast cancer along the disease continuum
  • Evaluate the efficacy and side-effect profiles of emerging agents and regimens for the treatment of breast cancer
  • Incorporate recent clinical trial evidence regarding the use of genomic and/or molecular biomarkers to individualize treatment selection for patients with early-stage or advanced/metastatic breast cancer


Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Joyce O’Shaughnessy, MD
Joyce O’Shaughnessy, MD
Celebrating Woman Chair in Breast Cancer Research
Baylor University Medical Center
Texas Oncology
Chair, Breast Cancer Research Program
The US Oncology Network
Dallas, TX

Disclosures: Consultant: AbbVie Inc., Agendia, Amgen, AstraZeneca, Bristol Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeutics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck & Co., Inc., Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Roche, Seattle Genetics, Syndax Pharmaceuticals, and Takeda.

Hope Rugo, MD, FASCO
Hope Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant Research Support: Pfizer, Merck & Co., Inc., Novartis, Lilly, Genentech, OBI Pharma, Odonate Therapeutics, Daiichi Sankyo, Eisai, Seattle Genetics, MacroGenics, and Immunomedics; Travel: Amgen, AstraZeneca, Daiichi Sankyo, MacroGenics, Merck & Co., Inc., Mylan, Pfizer, and Puma Biotechnology.

Henry M. Kuerer, MD, PhD, FACS, CMQ
Henry M. Kuerer, MD, PhD, FACS, CMQ
Executive Director, Breast Programs, MD Anderson Cancer Network
Robinson Endowed Distinguished Professor of Surgery and Cancer Research
Director, Breast Surgical Oncology Training Program
Department of Breast Surgical Oncology, Division of Surgery
The University of Texas MD Anderson Cancer Center
Houston, TX


Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By